Journal of Radiation Oncology

, Volume 8, Issue 3, pp 267–278 | Cite as

Patterns of utilization and comparative efficacy of altered fractionation and concurrent chemoradiation for treatment for T2N0M0 glottic carcinoma

  • Anesa AhamadEmail author
  • Sharon Salenius
  • Rudi Ross
  • Raj Selvaraj
  • Eduardo Fernandez
Original Research



To study radiotherapeutic treatment approaches in larynx-preservation for T2N0M0 glottic carcinoma at free-standing centers in the USA.


We retrospectively audited fractionation and chemoradiation at 59 centers in 5 geographic regions from 2000 to 2015. Chi-squared test and Fisher’s exact test were used to compare frequencies, the Cox proportional hazards model and Kaplan-Meier procedure were used for survival analyses, and log-rank test to compare survival curves.


Among 180 patients, chemoradiation, accelerated hypofractionation (2.25 Gy/fraction), and hyperfractionation was given to 14.4%, 13.3%, and 13.3%, respectively. Hypofractionation rates varied by geographic location: western/southern 33%, northeast 18.6%, Florida 5.6%, and Michigan 0% (p < 0.001). Conversely, hyperfractionation rates were as follows: Florida 23.6%, Michigan 14%, southern 9.5%, northeast and western 0% (p < 0.001). Hypofractionation increased from 6.3% in 2000–2004 to 25.0% in 2010–2015 (p < 0.001) and steadily declined for hyperfractionation. Chemoradiation did not vary by region but increased over time: 0% in 2000–2004, 17.6% in 2010–2015(p = 0.029).

At mean follow-up at 32.3 months, 36 months survivals were as follows: accelerated fractionation 85%, hyperfractionation 81%, and standard fractionation 66%, (p = 0.01); treatment duration < 50 days 82%, > 50 days 59% (p = 0.03). There was no difference in overall survival, progression-free survival, or locoregional-recurrence-free survival between chemoradiation and radiotherapy-only (all fractionations). Accelerated fractionation, (the fractionation with the highest survival) gave similar 36 months survivals as chemoradiation: 85% and 68%, respectively (p = 0.69). Chemoradiation worsened acute grades 2–4 toxicity rate versus radiotherapy-only: 80.8% and 54.5%, respectively (p = 0.01, univariate and multivariate).


Hypofractionation gave superior survival than standard fractionation for glottic T2N0M0 tumors. Its use varies among treatment centers but is increasing with time. Chemoradiation gave a lower therapeutic ratio: more than 30% greater acute toxicity without improvement of survival; yet, its use is growing over time. More explicit guidelines are needed.


T2 glottic Early larynx cancer Accelerated hypofractionation Head and neck squamous cell carcinoma Chemoradiation Patterns of care 



We wish to thank the patients who were the subjects of this study and the staff who provided care, 21st Century Oncology, FL, USA.


All authors contributed to the study conception and design.

Conceptualization and methodology were performed by Anesa Ahamad, Sharon Salenius, and Eduardo Fernandez.

Material preparation and data collection were performed by Rudi Ross.

Analyses were performed by Sharon Salenius.

Interpretation of the results was performed by Anesa Ahamad, Sharon Salenius, and Eduardo Fernandez.

Radiobiological calculations were performed by Raj Selvaraj.

Writing was performed by Anesa Ahamad.

Review and editing were performed by Anesa Ahamad, Sharon Salenius, and Eduardo Fernandez.

The first draft of the manuscript was written by Anesa Ahamad and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards


No funding was received for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of The Office for Human Research Protections of the U.S. Department of Health and Human Services and with the 1964 Helsinki declaration and with the Helsinki Declaration of 1975, as revised in 2008, and its later amendments or comparable ethical standards. This was a retrospective study and was approved by an appropriate ethics committee: an institutional Review Board.

Informed consent

Statement of informed consent was not applicable since the manuscript does not contain any patient data. This was a retrospective study. Prior to embarking on this study, an Institutional Review Board (IRB) reviewed the proposal and study description and granted a waiver of the requirement for individuals to provide signed consent for retrospective review of case files that was the procedure involved in this study.


  1. 1.
    Forastiere AA, Ismaila N, Lewin JS et al Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. - published online before print November 27, 2017
  2. 2.
    Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW (2001) T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 19:4029–4036CrossRefGoogle Scholar
  3. 3.
    Warde P, O’Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, Witterick IP, Payne D, Liu FF, McLean M, Waldron J, Cummings BJ (1998) T1-T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 41:347–353CrossRefGoogle Scholar
  4. 4.
    Stokes WA, Stumpf PK, Jones BL, Blatchford PJ, Karam SD, Lanning RM, Raben D (2017) Patterns of fractionation for patients with T2N0M0 glottic larynx cancer undergoing definitive radiotherapy in the United States. Oral Oncol 72:110–116. Epub 2017 Jul 18CrossRefPubMedGoogle Scholar
  5. 5.
  6. 6.
    Mendenhall WM, Takes RP, Shah JP, Bradley PJ, Beitler JJ, Strojan P, Suárez C, Rodrigo JP, Saba NF, Rinaldo A, Werner JA, Ferlito A (2015) Current treatment of T1N0 squamous cell carcinoma of the glottic larynx. Eur Arch Otorhinolaryngol 272(8):1821–1824. CrossRefPubMedGoogle Scholar
  7. 7.
    González Ferreira JA, Jaén Olasolo J, Azinovic I, Jeremic B (2015) Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: review of the literature. Rep Practi Onco Radiotherapy 20(5):328–339. CrossRefGoogle Scholar
  8. 8.
    Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC Cancer staging manual, 7th edn. Springer, New York, pp 57–67Google Scholar
  9. 9.
  10. 10.
    Cox JD, Stetz JA, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346CrossRefGoogle Scholar
  11. 11.
    Fowler JF (2010) 21 years of biologically effective dose. Br J Radiol 83(991):554–568. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Barendsen GW (1982) Dose fractionation. Dose-rate and iso-effect relationships for normal tissue responses. Intl J Radiat Oncol Biol Phvs 8:1991–1997Google Scholar
  13. 13.
    Fowler IF (1989) The linear-quadratic formula and progress in fractionation. Br J Radiol 62:679–694CrossRefGoogle Scholar
  14. 14.
    Garden AS, Forster K, Wong PF, Morrison WH, Schechter NR, Ang KK (2003) Results of radiotherapy for T2N0 glottic carcinoma: does the “2” stand for twice-daily treatment? Int J Radiat Oncol Biol Phys 55:322–328CrossRefGoogle Scholar
  15. 15.
    Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM (2010) T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 78:461–466CrossRefGoogle Scholar
  16. 16.
    Le QT, Fu KK, Kroll S et al (1997) Influence of fraction size, total dose, and overall time on local control of t1-t2 glottic carcinoma. Int J Radiat Oncol Biol Phys 39:115–126CrossRefGoogle Scholar
  17. 17.
    Yu E, Shenouda G, Beaudet MP, Black MJ (1997) Impact of radiation therapy fraction size on local control of early glottic carcinoma. Int J Radiat Oncol Biol Phys 37(3):587–591CrossRefGoogle Scholar
  18. 18.
    Kim TG, Ahn YC, Nam HR, Chung MK, Jeong HS, Son YI, Baek CH (2012) Definitive radiation therapy for early glottic cancer: experience of two fractionation schedules. Clin Exp Otorhinolaryngol 5(2):94–100CrossRefGoogle Scholar
  19. 19.
    Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M (2006) Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 64:77–82CrossRefGoogle Scholar
  20. 20.
    Moon SH, Cho KH, Chung EJ, Lee CG, Lee KC, Chai GY, Kang KM, Lee JY, Chung WK, Park WY, Kim JH (2014) A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother Oncol 110(1):98–103. CrossRefPubMedGoogle Scholar
  21. 21.
    Scott MT, Dosch A, Elsayyad N et al (2015) Therapeutic ratio of hypofractionation in early glottic cancer: a topic worth revisiting? Contemp Radiat Oncol 1:13–19Google Scholar
  22. 22.
    Schwartz DL, Sosa A, Chun et al (2017) SBRT for early-stage glottic larynx cancer-initial clinical outcomes from a phase I clinical trial. PLoS One 12(3):e0172055. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Horiot JC, Le Fur R, N’Guyen T et al (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231–241CrossRefGoogle Scholar
  24. 24.
    Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, Garden AS, Shenouda G, Harris J, Ang KK (2014) Final results of local-regional control and late toxicity of RTOG 90-03: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 89:13–20CrossRefGoogle Scholar
  25. 25.
    Trotti A, Zhang Q, Bentzen SM et al (2014) Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512). Int J Radiat Oncol Biol Phys 89(5):958–963. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kimura K, Itoh Y, Okada T et al (2015) Critical evaluation of a prospective study of concurrent chemoradiotherapy with S-1 for early glottic carcinoma. Anticancer Res 35(4):2385–2390PubMedGoogle Scholar
  27. 27.
    Hirasawa N, Itoh Y, Naganawa S, Ishihara S, Suzuki K, Koyama K, Murao T, Asano A, Nomoto Y, Horikawa Y, Sasaoka M, Obata Y (2012) Multi-institutional analysis of early glottic cancer from 2000 to 2005. Radiat Oncol 7(1):122. CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Taguchi T, Tsukuda M, Mikami Y, Horiuchi C, Ishitoya JI, Katori H (2006) Concurrent chemoradiotherapy with carboplatin and uracil-tegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx. J Laryngol Otol 120(6):478–481CrossRefGoogle Scholar
  29. 29.
    Bhateja P, Ward MC, Hunter GH, Greskovich JF, Reddy CA, Nwizu TI, Lamarre E, Burkey BB, Adelstein DJ, Koyfman SA (2016) Impaired vocal cord mobility in T2N0 glottic carcinoma: suboptimal local control with radiation alone. Head Neck 38(12):1832–1836. CrossRefPubMedGoogle Scholar
  30. 30.
    Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, Pignon JP, MACH-CH Collaborative Group (2011) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 100(1):33–40. CrossRefPubMedGoogle Scholar
  31. 31.
    Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14. CrossRefPubMedGoogle Scholar
  32. 32.
    Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P (2018) Immuno-oncology in head and neck squamous cell cancers: news from clinical trials, emerging predictive factors and unmet needs. Cancer Treat Rev 65:78–86. CrossRefPubMedGoogle Scholar
  33. 33.
    Davidi ES, Dreifuss T, Motiei M, Shai E, Bragilovski D, Lubimov L, Kindler MJJ, Popovtzer A, Don J, Popovtzer R (2018) Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer. Head Neck 40(1):70–78. CrossRefPubMedGoogle Scholar
  34. 34.
    O’Shea R, Byrne H, Tuckett J et al (2015) Impact of current smoking and alcohol consumption on gastrostomy duration in patients with head and neck cancer undergoing definitive chemoradiotherapy. JAMA Otolaryngol Head Neck Surg 141(5):463–469. CrossRefPubMedGoogle Scholar
  35. 35.
    Frowen J, Cotton S, Corry J, Perry A (2010) Impact of demographics, tumor characteristics, and treatment factors on swallowing after (chemo)radiotherapy for head and neck cancer. Head Neck 32(4):513–528. CrossRefPubMedGoogle Scholar
  36. 36.
    Khan MK, Koyfman SA, Hunter GK, Reddy CA, Saxton JP (2012) Definitive radiotherapy for early (T1-T2) glottic squamous cell carcinoma: a 20 year Cleveland Clinic experience. Radiat Oncol 7:193. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Stokes WA, Abbott D, Phan A, Raben D, Lanning RM, Karam SD (2017) Patterns of care for patients with early-stage glottic cancer undergoing definitive radiation therapy: a national cancer database analysis. Int J Radiat Oncol Biol Phys 98(5):1014–1021. CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA (2017) Hypofractionated radiotherapy for patients with early stage glottic cancer: patterns of care and survival. Natl Cancer Inst 109(10).

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Radiation Oncology21st Century OncologyFort MyersUSA
  2. 2.Department of Research and Education21st Century Oncology, 2234 Colonial BoulevardFort MyersUSA
  3. 3.Department of Research and Education21st Century Oncology, 2234 Colonial BoulevardFort MyersUSA
  4. 4.Department of Medical Physics21st Century OncologyPlantationUSA
  5. 5.Department of Radiation Oncology21st Century OncologyPlantationUSA

Personalised recommendations